Enbrel® is well tolerated across the following clinical indications1-7
Low rates of discontinuation due to AEs for up to 12 years1
Juvenile Idiopathic Arthritis
Established safety profile across clinical studies and real-life practice for up to 11 years2
Low rates of serious AEs, infections or malignancies over time3-5
Established safety profile for up to 5.5 years6
Established safety profile for up to 4 years7
AE, adverse event; axSpA, axial spondyloarthritis; JIA, juvenile idiopathic arthritis; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.